Fusen Pharmaceutical Company Limited
1652.HKHKSEHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
HK$0.82
−HK$0.14 · -14.58%
1652.HK company overview
Regular session · HKT · Market data may be delayed.
Company profile
Company websiteFusen Pharmaceutical Company Limited operates as an investment holding enterprise, primarily engaged in the manufacturing and distribution of a diverse range of pharmaceutical products across the People's Republic of China. Its extensive product portfolio includes specific cold remedies based on Shuanghuanglian, offered as both oral solutions and injections, alongside medications like flunarizine hydrochloride capsules and compound ferrous sulfate granules. The company further provides Yuanhu Zhitong oral solutions, Ganweikang tablets, and Yixinkang tablets. Beyond these, Fusen actively researches, develops, produces, and markets a variety of proprietary Chinese medicines and modern Western pharmaceuticals, targeting conditions such as colds, fevers, cardiovascular ailments, and anemia. Additionally, the firm offers business management and advisory services. Fusen Pharmaceutical Company Limited was established in 2003 and is headquartered in Nanyang, China.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Headquarters
- CN
- CEO
- Zhiming Cao
- Listed since
- Jul 11, 2018
- Employees
- 1,005
Market position
Day range
Current HK$0.82
52-week range
Current HK$0.82
- Open
- HK$0.955
- Previous close
- HK$0.96
- Volume
- 789K
- 7.66× average
- Average volume
- 103.03K
- Average daily volume
- Market cap
- 606.23M HKD
- Beta
- 0.27
- Market reference 1
- 50-day average
- HK$1.0458
- -21.59% below average
- 200-day average
- HK$0.9961
- -17.68% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 771.71M CNY
- P/E (TTM)
- -43.7×
- P/B (TTM)
- 1.58×
- P/S (TTM)
- 1.9×
- EV / EBITDA
- 66.84×
- Earnings yield
- -2.22%
- Free cash flow yield
- 13.17%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 40.16%
- Operating margin
- -0.63%
- Net margin
- -4.31%
- Return on equity
- -3.28%
- Return on assets
- -0.93%
- Return on invested capital
- -0.24%
Financial health
- Debt / equity
- 0.9×
- Current ratio
- 0.56×
Corporate actions
Annual dividends per share
Cash distributions grouped by calendar year; partial years are marked.
HK$0.0122
2021 complete year+2.5% since 2019
HK$0.0119
2,019
HK$0.0091
2,020
HK$0.0122
2,021
Corporate action history
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jun 7, 2022 | HK$0.0042Special | Jun 8, 2022 | Jun 30, 2022 |
Dividend | Sep 17, 2021 | HK$0.0068Semi-Annual | Sep 21, 2021 | Nov 19, 2021 |
Dividend | Jun 8, 2021 | HK$0.0054Semi-Annual | Jun 10, 2021 | Jul 16, 2021 |
Dividend | Sep 15, 2020 | HK$0.0051Semi-Annual | Sep 17, 2020 | Nov 27, 2020 |
Dividend | Jul 3, 2020 | HK$0.004Semi-Annual | Jul 7, 2020 | Aug 10, 2020 |
Dividend | Sep 13, 2019 | HK$0.0033Quarterly | Sep 16, 2019 | Nov 29, 2019 |
Ex-dividend Jun 7, 2022
HK$0.0042
Special
Record Jun 8, 2022 · Payment Jun 30, 2022
Ex-dividend Sep 17, 2021
HK$0.0068
Semi-Annual
Record Sep 21, 2021 · Payment Nov 19, 2021
Ex-dividend Jun 8, 2021
HK$0.0054
Semi-Annual
Record Jun 10, 2021 · Payment Jul 16, 2021
Ex-dividend Sep 15, 2020
HK$0.0051
Semi-Annual
Record Sep 17, 2020 · Payment Nov 27, 2020
Ex-dividend Jul 3, 2020
HK$0.004
Semi-Annual
Record Jul 7, 2020 · Payment Aug 10, 2020
Ex-dividend Sep 13, 2019
HK$0.0033
Quarterly
Record Sep 16, 2019 · Payment Nov 29, 2019
1652.HK peers
Continue in GoAI
Research 1652.HKresearch.disclaimer